Details of the Drug

General Information of Drug (ID: DMOCHVE)

Drug Name
SL-401
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1/2 [1]
Blastic plasmacytoid dendritic cell neoplasm 2A60.5 Phase 1/2 [1]
Multiple myeloma 2A83 Phase 1/2 [2]
Myeloproliferative neoplasm 2A20 Phase 1/2 [2]
Cross-matching ID
TTD ID
D0Z2ZY
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 3 receptor (CSF2RB) TTPYS82 IL3RB_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02113982) SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92.